One of the best ways for clinical trial results to reach the scientific community as well as the public community is through publication in a medical or scientific journal. If a company conducting a clinical trial can do that, and the results are positive, there’s a strong chance they will start to reap some major benefits. Benefits like, for example, a more than 100% surge in its stock.
That’s what happened to Tenax Therapeutics Inc. (NASDAQ:TENX) anyway.
What Happened?
Yesterday, Tenax Therapeutics announced that its positive preclinical study of levosimendan will be published in the March 1, 2018, issue of Pulmonary Circulation. This is a global, peer-reviewed research journal that focuses primarily on pulmonary circulation and pulmonary vascular disease. When conducting research, you should always cite peer-reviewed journals as they are your best bet for a credible source. That’s why I think it’s so significant that Tenax Therapeutics is going to be featured in this month’s issue.
The Morrisville, North-Carolina based company has had two studies published in recent months, which is even more impressive. It appears the stock market thinks the same thing. As of right now, Tenax Therapeutics is trading at $9.81 on the Nasdaq Exchange. It opened Thursday at $4.51. This puts the stock up $5.17, or a whopping 111.42%.
Tenax Therapeutics Positive Preclinical Trial
The preclinical study looked at the impact of levosimendan in an experimental model of right heart failure. Dr. Hansen and his colleagues discovered that chronic administration of levosimendan significantly improved right heart function. Based on the results, the team of researchers at Tenax Therapeutics believe the results support the possible clinical use of levosimendan, which is a calcium sensitizer, to treat right ventricular failure. This is when there is pressure, volume overload, or myocardial disease which then causes the right ventricle to fail.
The Takeaway
This is extremely exciting news for Tenax Therapeutics, so I’m not surprised to see the stock soaring. That said, a more than 100% surge this early in the trading day makes it all the more impressive.
>>HealthSpace Announces Contract With The Tennessee State Department Of Health
You can find the study in the Pulmonary Circulation journal under the title of “Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure.”
Featured Image: Twitter
